ArticleTransplantation and cellular therapy2022

Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients.

Muneyoshi Kimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.